TC
CRVS icon

Truvestments Capital’s Corvus Pharmaceuticals CRVS Stock Holding History

Truvestments Capital’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$152K Sell
10,195
-62
-0.6% -$860 0.02% 350
2026
Q1 		$150K Hold
10,257
– – 0.03% 335
2025
Q4 		$79K Buy
10,257
+4,744
+86% +$37.4K 0.01% 380
2025
Q3 		$40.6K Buy
5,513
+738
+15% +$3.78K 0.01% 475
2025
Q2 		$19.1K Buy
+4,775
New +$17.4K ﹤0.01% 544

Other funds holding CRVS

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Truvestments Capital's CRVS Position: Q2 2026 in Review

Truvestments Capital reduced its Corvus Pharmaceuticals (CRVS) stake by 0.6% in Q2 2026, selling an estimated $860 and leaving 10,195 shares worth $152K. The position accounts for 0.02% of the portfolio, ranked #350.

Truvestments Capital first reported a position in CRVS in Q2 2025 and has held it in 5 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Truvestments Capital held 10,195 shares of Corvus Pharmaceuticals worth $152K as of Q2 2026.
  • Truvestments Capital sold 62 Corvus Pharmaceuticals shares in Q2 2026, an estimated $860.
  • Corvus Pharmaceuticals made up 0.02% of Truvestments Capital's portfolio in Q2 2026, its #350 holding.
  • Truvestments Capital first reported a position in Corvus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.